Spectral AI Inc Stock Price, News & Analysis

Spectral AI (NASDAQ:MDAI), an AI medical diagnostics company focused on wound care, reported its Q2 2025 financial results. The company achieved $5.1 million in R&D revenue for Q2 and $11.8 million for H1 2025. A significant milestone was reached with the completion of their De Novo FDA application submission for the DeepView System in June 2025.

Financial highlights include a cash position of $10.5 million, up from $5.2 million in December 2024, supported by a $15 million debt financing agreement with Avenue Capital Group. The company reported a Q2 net loss of $7.9 million, primarily due to warrant liability adjustments. Gross margin was 45.2%, slightly down from 46.6% in Q2 2024. Management reaffirmed full-year 2025 revenue guidance of $21.5 million.

Spectral AI (NASDAQ: MDAI), a company specializing in AI-driven medical diagnostics for wound care through their DeepView® System, has scheduled its Q2 2025 financial results announcement for August 12, 2025 after market close.

The company will host a conference call at 5:00 PM ET on the same day to discuss the results. Investors can participate by dialing 833-630-1956 (U.S.) or 412-317-1837 (International). A simultaneous webcast will be available on the company's investor relations website.

Spectral AI (NASDAQ: MDAI) has submitted a De Novo 510k marketing clearance application to the FDA for its DeepView® System, a breakthrough medical device designed for burn care settings. The DeepView System, which received FDA Breakthrough Device Designation in 2018, combines multi-spectral imaging with AI algorithms to predict burn wound healing potential.

The system provides non-invasive healing predictions on the day of injury and up to 7 days post-injury, enabling clinicians to make earlier and more informed treatment decisions. The De Novo regulatory pathway was chosen due to the technology's novel nature, as no predicate device exists in the U.S. market.

The development has been supported by federal funds from the U.S. Department of Health and Human Services, Administration for Strategic Preparedness and Response, and BARDA through multiple contract awards since 2013, with the current contract number being 75A50123C00049.

Spectral AI showcased its DeepView System at the British Burn Association conference in Brighton, UK from June 4-6, 2025. The technology was featured in multiple presentations highlighting its impact on burn care. Key findings from Dr. Jeffrey Carter revealed that DeepView significantly improved clinicians' ability to detect non-healing wounds, increasing detection rates from 61% to 89% (p < 0.0001). Mr. Chris Wearn from Bristol Adult Burns Service shared positive early experiences, noting the device's portability and ease of use in supporting clinical decision-making. The conference featured several presentations focusing on AI-enhanced multispectral imaging for burn wound assessment, including studies on patient experience and wound healing prediction accuracy. The DeepView System's presence at this premier burn care event demonstrates Spectral AI's commitment to advancing burn treatment technology and improving patient outcomes.

Spectral AI (NASDAQ: MDAI) has appointed Stanley Micek as permanent Chief Operating Officer, following his successful tenure as Interim COO since May 2024. Micek brings over 25 years of healthcare leadership experience, including previous roles as Senior Vice President for Business Development & Strategy at MiMedx and leadership positions at The Ohio State University Comprehensive Cancer Center. In his interim role, he has led the company's Research and Development group and overseen various teams working on FDA submission for their AI-powered wound diagnostic tool. Board Chairman Dr. J. Michael DiMaio praised Micek's exceptional leadership, operational insight, and ability to drive performance and cross-functional collaboration.

Spectral AI (NASDAQ: MDAI) held its 2025 Annual Meeting of Stockholders with 60.8% of total shares represented (15,551,068 shares). Stockholders approved both proposed items: the election of six directors to the Board and the ratification of KPMG LLP as the independent registered public accounting firm for fiscal year 2025. The elected board members include Colin Bristow (Head of Healthcare at SIM IP), Richard Cotton (Audit Committee Chairman), Dr. J. Michael DiMaio (Founder and Board Chairman), Martin Mellish (Aspen Advisory Services), Deepak Sadagopan (Risant Health), and Marion Snyder (Shockwave Medical).

Spectral AI's (NASDAQ: MDAI) DeepView® System has achieved a remarkable 95.3% accuracy in burn healing assessment, as published in the prestigious Burns journal. The multi-center clinical study validates the system's effectiveness in using AI-driven multi-spectral imaging to predict burn healing potential across diverse clinical settings.

The technology enables clinicians to make earlier, more informed decisions about healing time and surgical requirements, potentially improving patient outcomes. This publication in Burns, a leading peer-reviewed medical journal of the International Society for Burn Injuries, represents the first multi-center evaluation of AI-enhanced multispectral imaging in burn assessment.

Spectral AI (NASDAQ: MDAI) announced that its research partners, RCSI Skin Wounds and Trauma Research Center and RCSI Connolly Hospital, have won the Best Research Project at the 2025 Education Awards for their Diabetic Foot Ulcers project using the DeepView System. The project showcased the integration of real-time multispectral imaging with AI-driven analytics to improve evaluation and treatment strategies for diabetic foot ulcers. The Education Awards, part of the BusinessRiver network connecting over 12,000 senior professionals, recognize excellence in third-level education across Ireland. This achievement validates the clinical value of Spectral AI's DeepView System and generates valuable real-world data as the company prepares for broader market commercialization.

Spectral AI (NASDAQ: MDAI) reported its Q1 2025 financial results, highlighting R&D revenue of $6.7 million, up 6.0% from Q1 2024, and improved cash position of $14.1 million. The company achieved net income of $2.9 million, compared to a $3.2 million loss in Q1 2024. Key developments include completing a $15 million debt financing agreement with Avenue Capital Group (initial draw of $8.5 million) and raising $2.7 million in equity financing. The company completed its Burn Validation Study in March 2025, involving 164 patients, demonstrating superior performance of its DeepView System compared to clinical judgment. Spectral AI maintains its FY2025 revenue guidance of $21.5 million and plans FDA De Novo submission in H1 2025.